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INTRODUCTION
Recombinant human growth hormone (rhGH) is used to
treat growth hormone deficiency (GHD), statural disorders
associated with Turner syndrome, chronic renal failure, Prad-
er-Willi syndrome, intrauterine growth retardation, idiopath-
ic short stature (ISS) and AIDS wasting in adults in the Unit-
ed States (1). GH replacement therapy has been shown to pr-
omote statural growth in children with GHD and with short
stature due to other causes (2). The use of rhGH in adults
having GHD has been shown to decrease their excess fat mass,
increase lean mass (3), increase bone mineral density (BMD)
(4), improve lipid profile (5, 6), and in some cases, improve
the quality of life and physical performance (3, 7). GHD is
known to be associated with cognitive impairment. More-
over, there is evidence that cognitive performance, particu-
larly attention and memory, is improved by GH replacement
therapy in GHD patients (8, 9). In addition, it has been sug-
gested that the decline in GH and insulin-like growth fac-
tor I (IGF-I) that is observed with advancing age may con-
tribute to impaired cognitive function associated with aging
(10, 11). Further, it was proved that growth hormone-releas-
ing hormone (GHRH) treatment, which brings about an in-
crease in the GH and IGF-I levels, improved performance on
a number of cognitive tasks in healthy normal elderly (12).
The association between GH and cognitive processes has
also been supported by studies on rats. It was demonstrated
that GH and GHRH facilitated long-term memory in young
rats, and GH delayed the extinction response in both young
and aged rats (13). Madeleine et al. (14) reported that GH
replacement in hypophysectomized (HYPOX) rats, 1) im-
proved spatial memory (a form of long-term memory) as ob-
served in the Morris water maze (MWM) test and, 2) affect-
ed hippocampal levels of N-methyl-D-aspartate (NMDA)
receptor subunit and post-synaptic density (PSD)-95 gene
transcript levels in the glutamatergic neurotransmission sys-
tem. HYPOX rat is a well-known animal model of GHD,
and the hippocampus has an essential role in spatial memo-
ry in both humans and rats (15). The MWM test is a mem-
ory test based on the capacity of animals to rescue themselves
by reaching a hidden goal platform in a pool of water (16).
Rats with a damaged hippocampus display spatial navigation
impairments and perform poorly in the MWM test (16).
We hypothesized that GH replacement in HYPOX fe-
male Sprague-Dawley rats would, 1) stimulate somatic gro-
wth as estimated from their body weights and the width of
the proximal tibial growth plate and, 2) improve cognitive
function as evaluated by the MWM test. We also evaluated
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Comparative Study of the Effects of Different Growth Hormone Doses
on Growth and Spatial Performance of Hypophysectomized Rats
This study was designed to examine the effects of recombinant human growth hor-
mone replacement on somatic growth and cognitive function in hypophysectomized
(HYPOX) female Sprague-Dawley rats. Rats (5 per group) were randomized by
weight to 3 experimental groups: group 1, administered 200 μ g/kg of GH once daily
for 9 days; group 2, administered 200 μ g/kg of GH twice daily; and group 3, adminis-
tered saline daily. Somatic growth was evaluated by measurement of body weight
daily and of the width of the proximal tibial growth plate of the HYPOX rats. Cogni-
tive function was evaluated using the Morris water maze (MWM) test. The results indi-
cated that GH replacement therapy in HYPOX rats promoted an increase in the
body weight and the width of the tibial growth plate in a dose-dependent manner.
On the third day of the MWM test, the escape latency in the GH-treated groups 1
and 2 was significantly shorter than that in the control rats (P<0.001 and P=0.032,
respectively), suggesting that rhGH improved spatial memory acquisition in the
MWM test. Therefore it is concluded that rhGH replacement therapy in HYPOX rats
stimulates an increase in somatic growth in a dose-dependent manner and also
has beneficial effects on cognitive functions.
Key Words : Growth Hormone; Hypophysectomized Rat; Somatic Growth; Cognitive Function; Morris Water
Maze Test
Received : 24 December 2007
Accepted : 25 October 2008the dose effects of GH on somatic growth and cognitive fu-
nction.
MATERIALS AND METHODS
Animals
HYPOX female Sprague-Dawley rats aged 51-58 days
and weighing 90-100 g at study initiation were supplied by
LG Life Science. They were hypophysectomized at 25-30
days of age. The rats were weighed at 37-44 days of age, and
only healthy rats were retained. The retained rats were rewei-
ghed 7 days later, and only those rats that were in good health
and had not gained or lost >10% of their body weight in
the previous 7-day period were selected. We followed the
USP30-NF25 procedure with somatotropin from the US Ph-
armacopeia (USP), which is a standard procedure used for
GH bioassay using an animal model. 
The rats were housed under standardized conditions (12-
hr light and 12-hr dark cycle; lights switched on at 0800 hr;
temperature, 21-26℃; humidity, 40-60%). Food and drink-
ing water were available in the cages. Body weight was mea-
sured at 0800 hr everyday. Rats (5 per group) were random-
ized by weight to 3 experimental groups as follows. The rats
in group 1 were administered daily subcutaneous injections
of 200 μ g/kg of rhGH (Growtropin
�; Dong-A Pharm, Seoul,
Korea) at 0800 hr. The rats in group 2 were administered
subcutaneous injections of 200 μ g/kg of rhGH twice daily
at 0800 and 2000 hr. The rats in group 3 (control group)
were administered daily subcutaneous injections of saline at
0800 hr. The animals were treated in this manner for 9 days.
All animal experiments were performed with the approval
of the Institutional Animal Care and Use Committee, Labo-
ratory Animal Research Center, Samsung Biomedical Rese-
arch Institute, Seoul, Korea. All procedures conformed to the
international guidelines for the ethical use of laboratory ani-
mals and efforts were made to minimize the number of ani-
mals used and to avoid any unnecessary suffering.
MWM performance test
Spatial learning and memory were evaluated in the GH-
treated and control rats by using a modification of the MWM
performance test (16). The MWM test is a memory test based
on the capacity of animals to rescue themselves by reaching
a hidden goal platform in a pool of water (16). The MWM
test was conducted in a circular water-maze tank (diameter,
157 cm and height, 60 cm) filled with water (temperature,
24±1℃) that had been opacified by adding powdered milk.
A transparent Plexiglass platform (diameter, 10 cm and hei-
ght, 47 cm) was submerged 3 cm below the water surface and
placed in the one of the quadrants. The maze was located in
the center of a well-lit room and was surrounded by black
curtains (placed at 50 cm from the pool periphery) that con-
tained 4 distinct visual cues. The swimming path of each rat
was monitored by an overhead video camera connected to a
personal computer and was analyzed by an automated track-
ing system (Smart v.20
�; Panlab SL, Barcelona, Spain) (Fig.
1). During the training period, the animals were required to
locate the hidden platform, which remained in the same posi-
tion, in relation to the external visual cues. The training was
carried out in 1 block of 3 trials per day. To begin each trial,
the rats were placed in the water facing the maze wall in one
of the 3 quadrants except the target quadrant containing the
hidden platform. The daily order of entry into individual
quadrants was randomized. Each trial ended once the animals
found the platform; if the rats were unable to find the plat-
form within 90 sec, they were guided toward it by an exper-
imenter. After a period of 30 sec on the platform, the rats
were immediately re-placed at a different start position for
the next trial. At the end of a training session, the rats were
dried and returned to their respective home cages. In each
trial, the time taken for the rat to reach the platform (escape
latency in seconds), the length of the swim path (distance in
centimeters), and the swimming speed (centimeters/second)
were measured. The water maze training procedure began
on experimental day 5, and the test was given for 5 consec-
utive days. On day 9, probe trials were conducted at 2 hr after
completion of training in order to evaluate spatial bias. The
rats were released from the quadrant opposite to where the
platform was located and were allowed to swim for 90 sec in
the absence of the platform. We measured the percentage of
time that the rats spent in the area corresponding exactly to
the area occupied by the platform during the training peri-
od. Considering the fact that rats are nocturnal animals, all
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Fig. 1. The automated tracking system (Smart v.20
�) used in the
Morris water maze (MWM) test. There is a circular platform in the
one of the quadrants. The 3 quadrants except the target quadrant
that contained the hidden platform were used for entry during each
trial on a particular day. The escape latency (the time taken to reach
the hidden platform), the length of the swim path, and the swim-
ming speed were measured automatically.MWM tests were performed during the dark cycle.
The width of the proximal tibial growth plate
On day 10, the animals were euthanized, and their tibias
were harvested and fixed in 10% neutral buffered formalin.
The fixed tibias were split along the frontal plane at the prox-
imal end. The tibias were processed for paraffin embedding,
sectioned, and stained with hematoxylin and eosin. The mea-
surement of the width of the proximal tibial growth plate was
performed on the left tibia. We obtained 3 measurements
per section (medial, central, and lateral) at a magnification
of ×100 under a light microscope. In all rats, the means of
the 3 sections were averaged to obtain the width of the prox-
imal tibial growth plate.
Statistical analysis
Due to its nature, the data were analyzed by non-paramet-
ric means and have been expressed as the median and inter-
quartile ranges. The Kruskal-Wallis test was used for com-
paring the medians of several variables among the groups.
When the differences between the medians were significant,
a multiple comparison test using LSD was performed. Anal-
ysis of weight gain and improvement in the MWM test were
evaluated using the Wilcoxon signed-ranks test. All statisti-
cal analyses were performed using SPSS version 11 (SPSS Inc.,
Chicago, IL, U.S.A.), and P<0.05 was considered as statisti-
cally significant.
RESULTS
Cumulative body weight gain and the width of the
proximal tibial growth plate of HYPOX rats
We compared the relative dose-dependent effects of GH
on stimulation of somatic growth in HYPOX rats. The gro-
wth parameters measured included weight gain and bone
growth (the width of the tibial growth plate). Cumulative
body weight gain and the width of the tibial growth plate in
the experimental groups are presented in Table 1. The daily
body weights of the groups are shown in Fig. 2. 
There was no difference in the baseline body weight among
the 3 groups. However, body weight development differed
significantly, as observed by comparing the weight before GH
treatment with that after GH treatment. Body weight rem-
ained constant in the control rats (P=1.000). It was expect-
ed because no weight gain was the postulation of adequate
hypophysectomy. A significant weight gain was demonstrat-
ed when GH was administered by either once daily injection
(median weight gain, 12 g; P=0.042) or twice daily injection
(median weight gain, 22 g; P=0.043). The rats which received
200 μ g/kg of GH twice daily gained significantly more wei-
ght than those who received 200 μ g/kg of GH once daily
(P=0.003) or saline (P=0.000). The cumulative weight gain
of the rats which received 200 μ g/kg of GH twice daily was
approximately twice that of the rats who received 200 μ g/kg
of GH once daily, suggesting that GH stimulated an increase
in the body weight of HYPOX rats in a dose-dependent man-
ner.
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Data are expressed as the median and interquartile ranges.
Group 1, rhGH 200 μ g/kg subcutaneously once daily; Group 2, rhGH
200 μ g/kg subcutaneously twice daily; Group 3, Saline subcutaneously
once daily.
*P=0.982; 
� P=0.002, Group 1 vs. Group 2: P=0.003, Group 1 vs. Group 3:
P=0.001, Group 2 vs. Group 3: P=0.000; 
� P=0.028, Group 1 vs. Group
2: P=0.040, Group 1 vs. Group 3: P=0.263, Group 2 vs. Group 3: P=
.005.
Statistical analysis: Kruskal-Wallis test with post hoc LSD.
Initial body 
Cumulative  Width of the tibial 
Group
weight (g)*
body weight growth plate (μ m)
�
gain (g)
� on day 10
1 88.0 (86.5-115.0) 12.0 (10.0-18.5) 260 (240-270)
2 90.0 (85.0-116.0) 22.0 (19.0-30.0) 303 (268-333)
3 89.0 (86.5-105.5) 0.0 (-3.0-3.0) 223 (205-265)
Table 1. Effects of rhGH replacement therapy for 9 days on body
weight gain and the width of the proximal tibial growth plate in
hypophysectomized (HYPOX) rats (5 rats per group)
Fig. 2. Effects of rhGH on body weight of HYPOX rats. Body weig-
hts were measured over 10 days. GH was administered for 9 days.
Weight gain in each group was analyzed using the Wilcoxon sig-
ned-ranks test. A significant weight gain was evident only in groups
1 and 2. Data are represented as the median and interquartile ra-
nges (5 rats per group).
Group 1: rhGH 200 μ g/kg subcutaneously once daily, P=0.042.
Group 2: rhGH 200 μ g/kg subcutaneously twice daily, P=0.043.
Group 3: Saline subcutaneously once daily, P=1.000.
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DaySimilar relative results among the 3 groups were obtained
on measurement of the width of the tibial growth plate (Table
1). In rats which received 200 μ g/kg of GH twice daily, the
tibial growth plate was significantly wider as compared to
the rats which received 200 μ g/kg GH once daily (P=0.040)
or saline (P=0.005). However, there was no significant dif-
ference in the width of the tibial growth plate between groups
1 and 3 (P=0.263). The representative stained sections of the
tibial growth plate of HYPOX rats from the different exper-
imental groups are shown in Fig. 3.
MWM performance test
The MWM test was performed from experimental days 5
to 9. The escape latencies of the HYPOX rats on each day
during the training period are shown in Fig. 4. On day 5, the
median escape latency in groups 1, 2, and 3 was 61.5, 58.5,
and 62.1 sec, respectively. On day 9, i.e., after training for 5
days, the median escape latency in groups 1, 2, and 3 was
35.6, 35.6, and 36.3 sec, respectively. In other words, during
memory acquisition testing over the day, the escape latency
was noted to have decreased in all groups. However, the dec-
rease was statistically significant only in group 2 (P=0.043)
and group 3 (P=0.043). There was no difference in the swim-
ming speed among the groups or within the rats in a group
on any day. Thus, the decrease in the escape latency indicat-
ed that the HYPOX rats in all the 3 groups were learning
the behavioral task. On the last day of training, there was no
difference in the escape latency among the 3 groups. How-
ever, the daily rate of decrease in escape latency was higher
in the GH-treated groups 1 and 2 than in the control group.
On day 7, the escape latency in the GH-treated groups 1 and
2 was significantly shorter than that in the control group (P=
0.000 and P=0.032, respectively). This result indicated that
GH-treated HYPOX rats had more rapid memory acquisi-
tion in the MWM test. On day 7, the rats which received
200 μ g/kg of GH once daily had a shorter escape latency than
those who received 200 μ g/kg of GH twice daily (P=0.023);
therefore, it could not be demonstrated that the higher the
dose of GH, the better was the performance in the MWM
test. On day 9, probe trials were conducted at 2 hr after com-
pletion of training in order to evaluate spatial bias. There was
no difference between the percentage of time spent by the rats
in the area corresponding exactly to the area occupied by the
platform during the training period. 
DISCUSSION
The purpose of the present study was to examine the effects
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Fig. 3. Representative stained sections of the tibial growth plates of
HYPOX rats. Arrows indicate the width of the proximal tibial growth
plate. (A) Group 1: rhGH 200 μ g/kg subcutaneously once daily, (B)
Group 2: rhGH 200 μ g/kg subcutaneously twice daily, (C) Group 3:
Saline subcutaneously once daily. The width of the tibial growth
plate is thicker in B than in A and C (P=0.040 and P=0.005, respec-
tively) (H&E stained, ×100).
A
C
Bof different GH doses on 1) somatic growth as estimated from
body weight and width of the tibial growth plate and 2) spa-
tial performance as examined by the MWM test in HYPOX
female Sprague-Dawley rats. HYPOX rats have multiple
pituitary hormone deficiencies, including GHD. We followed
the USP procedure to obtain the HYPOX rats. According
to this procedure, the HYPOX rats would not gain weight
due to multiple pituitary hormone deficiencies, which, accord-
ing to the USP is a standard method for GH bioassay using
an animal model. HYPOX rats have been used to evaluate
the effects of GH in several previous studies (14, 17, 18). Our
results suggest that rhGH replacement therapy stimulates ra-
pid weight gain accompanied with actual bone growth (mea-
sured by the width of the tibial growth plate) in HYPOX
rats. Although there was no significant statistical difference
in the width of the tibial growth plate between groups 1 and
3, median of the width of the tibial growth plate in group 1
was approximately 40 μ m wider than group 3. Moreover, the
same GH doses that stimulated growth also improved spa-
tial performance as observed in the MWM test. Spatial mem-
ory is a form of long-term memory. In this study, rats which
received GH had more rapid spatial memory acquisition than
the control rats. On the third day of trial of the MWM test,
the escape latency of the GH-treated rats was significantly
shorter than that of the control rats. However, it was not obvi-
ous whether GH affects spatial memory in a dose-dependent
manner because the escape latency in rats who received 200
μ g/kg of GH once daily was shorter than that in rats who
received 200 μ g/kg of GH twice daily, indicating that a GH
dose of 200 μ g/kg/day is sufficient to improve spatial mem-
ory as observed in the MWM test. After training over five
days, the spatial performance of all HYPOX rats had improv-
ed as observed in the MWM test, indicating that they were
learning the behavioral task. And there was no difference in
the escape latency among the groups on the fifth day of trial.
It is considered that the effect of repeated trial exceeds the
effect of GH after five days. And it is also possible that GH
receptors in the brain are saturated in GH-treated rats.
Madeleine et al. (14) reported similar results. They admin-
istered 1 mg/kg of GH twice daily to HYPOX rats in order
to evaluate spatial memory using the MWM test. The rhGH-
treated rats had a significantly better spatial memory task
performance than the control rats on the second and third
days of the trial. Further training eliminated this difference
between the groups, which was consistent with our results.
In the previous study (19), administration of twice daily
GH injections (1 mg/kg) did not increase the serum IGF-I
concentration in GH-deficient rats. In contrast, continuous
infusions of GH (2.4 mg/kg/day) resulted in a 5-fold increase
in the serum IGF-I concentration. Both modalities of GH
administration caused significant weight gain, although the
growth rate was significantly greater in rats which were ad-
ministered GH by continuous infusion. The increase in the
serum IGF-I concentration by continuous GH infusion may
be due to up-regulation of the liver membrane GH recep-
tors (20). Moreover, GH also has a short circulating half-life
(21). Therefore, a more frequent dosing schedule would en-
hance IGF-I production and provide a pattern of circulating
GH and IGF-I that more closely resembles the physiologi-
cal state (22). Therefore, here, twice daily administration of
GH was employed in order to increase the daily dose of GH.
We did not measure the serum IGF-I concentration because,
according to a previous study, twice daily injection of GH
could not be expected to increase serum IGF-I concentrations
(19).
It has been reported that GH acts directly on the growth
plate, and the presence of GH receptors on rat chondrocytes
(23) and human growth plates (24) has been demonstrated.
Therefore, we selected body weight and the width of the tib-
ial growth plate instead of serum IGF-I concentration as the
measurement criteria to evaluate the effects of GH on somat-
ic growth and to minimize stressful events such as blood sam-
pling, which might have influenced the performance in the
MWM test.
Our results suggest that GH stimulates an increase in the
body weight and the width of the tibial growth plate in
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Fig. 4. Effects of rhGH treatment of HYPOX rats on performance
in the MWM test from experimental days 5 to 9. The training was
carried out in 1 block of 3 trials per day for 5 consecutive days.
Improvements in the performance in the MWM test were evaluated
using the Wilcoxon signed-ranks test (Group 1, P=0.080; Group
2, P=0.043; Group 3, P=0.043). *P=0.027, using Kruskal-Wallis
test with Bonferroni’s correction. The data obtained on day 7 were
subjected to a multiple comparison test was performed using LSD.
Data are represented as the median and interquartile ranges (5
rats per group).
On day 7, Group 1 vs. Group 2: P=0.023.
Group 1 vs. Group 3: P=0.000.
Group 2 vs. Group 3: P=0.032.
Group 1: rhGH 200 μ g/kg subcutaneously once daily.
Group 2: rhGH 200 μ g/kg subcutaneously twice daily.
Group 3: Saline subcutaneously once daily.
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*HYPOX rats in a dose-dependent manner. Short-term GH
treatment of adults with GHD increases body sodium and
extracellular water resulting in an increase in the body weight
(25); thus, the increase in the width of the tibial growth plate
in this study reflects the fact that short-term GH replacement
therapy stimulates actual organ growth. Further, the doses
employed in our study (200 μ g/kg of rhGH once or twice
daily) have physiological effects on HYPOX rats. Generally,
the dosage of GH used in children with GHD is 166-236 μ g/
kg/day.
It is well known that longitudinal bone growth is the result
of chondrocyte proliferation and subsequent proliferation of
the growth plate of a long bone (26). It has been reported that
in cultured growth plate chondrocytes, GH acts on the rest-
ing zone chondrocytes and is responsible for local IGF-I pro-
duction, which stimulates clonal expansion of proliferating
chondrocytes in an autocrine/paracrine manner (27). Since
IGF-I gene deletion causes dwarfism in mice (28) and extreme
short stature in humans (29), IGF-I is believed to play an im-
portant role in longitudinal bone growth. Nevertheless, the
finding that administration of GH increases the width of the
growth plate germinal zone in IGF-I-deficient mice indicates
a direct role of GH in proliferation of the growth plate (28).
A more interesting issue is the relationship between GH
and cognitive function. Children with GHD have significant
cognitive deficits, which may be moderated by GH treatment
(30). Several studies have demonstrated that in adults with
GHD, GH improves the quality of life and cognitive per-
formance (8). There is also emerging evidence that the decline
in GH and IGF-I observed with advancing age may contri-
bute to the impairment in cognitive function associated with
aging (10, 11, 31), and such age-related changes may be ar-
rested or partially reversed by hormonal supplementation (12).
In addition, it has been suggested that in the healthy elderly,
a positive correlation exists between IGF-I levels and cogni-
tion (11).
The association between GH and cognitive processes has
also been supported by studies on rats. GH was found to facil-
itate long-term memory in young but not in elderly rats; in
contrast, the extinction response as recorded in a behavioral
assay was affected in both young and aged rats (13).
The physiological and molecular mechanisms behind the
improvement in cognitive functions after GH treatment are
unclear. The existence of GH-binding sites in brain areas, such
as the hippocampus, hypothalamus, putamen, and choroid
plexus, has been reported (32). The action of GH in the cen-
tral nervous system could be due to its direct effects on cells
or due to GH-induced release of secondary mediators, such
as IGF-I, that can cross the blood-brain barrier. It has been
demonstrated that subcutaneous administration of physio-
logical doses of GH to patients with GHD is associated with
an increase in GH concentration in the cerebrospinal fluid
(33). In addition, IGF-I receptors are widely distributed in
the brain (34). Administration of IGF-I improved working
memory and reference memory in the MWM test in male
rats (35). 
In a mouse model, it was suggested that the NMDA recep-
tors in the hippocampus were an essential component of long-
term potentiation, which plays an important role in spatial
memory acquisition (36). The hippocampus is considered to
be vital in multiple cognitive processes, particularly learn-
ing and memory. Lesions of the hippocampus and pharma-
cological blockade of the NMDA receptors disrupt spatial
learning (16, 37). In comparison, increased expression of the
NR2B subunit of the NMDA receptor in the forebrain en-
hances hippocampal learning (38). These findings have led
to the view that normal spatial learning requires the integri-
ty of NMDA receptor-mediated plasticity in the hippocam-
pus (39).
The NMDA receptor complex consists of several types of
subunits, including type 1 (NR1), type 2A (NR2A), and type
2B (NR2B) (40), and it is closely related to the PSD-95 pro-
tein family, which is thought to be responsible for the molec-
ular organization of the synaptic NMDA receptors and sub-
sequent signal transduction (41).
Madeleine et al. (42) demonstrated that GH may elicit an
increase in the hippocampal GH receptor and NMDA recep-
tor subunit NR2B gene transcript levels in young male Sp-
rague-Dawley rats. They also confirmed a distinct interac-
tion between GH and the NMDA receptor, which was sup-
ported by the positive correlation between the GH receptor
and NR2B mRNA levels. However, the molecular mecha-
nism by which GH influenced the expression of the NMDA
receptor subunit gene transcripts in the hippocampus was
unclear. Therefore, they examined the effect of daily subcu-
taneous injection of human IGF-I for 10 days in male rats
belonging to different age groups (43). The result was that
the NR2B subunit mRNA expression increased in the young
(age, 11 weeks) but not in the elderly (age, 14-16 months)
rats, and NR2A mRNA expression decreased in both groups.
These results suggested that IGF-I might have mediated the
actions of GH. Thereafter, they reported that rhGH treat-
ment of HYPOX rats did not alter expression level of the
NMDA receptor subunit NR2B gene, although there were
improvements in the MWM test in the GH-treated HYPOX
rats. However, the NR2A and PSD-95 gene transcript lev-
els were elevated by rhGH treatment. Therefore, they sug-
gested that the NR2A subunit was likely to play an impor-
tant role in learning, and there was a link between the per-
formance in the MWM test and PSD-95.
Another study demonstrated that hippocampus-dependent
learning ability selectively correlates with the NR1 subunit
immunofluorescence levels in the CA3 neurons of the hip-
pocampus (39). From these results, it is obvious that hippo-
campal NMDA receptors may play an important role in le-
arning and memory. However, most critical subunit of the
NMDA receptor remains unclear.
In conclusion, this study demonstrates that 1) GH replace-
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motes increase in somatic growth as observed from measure-
ment of the body weight and the width of the tibial growth
plate and 2) GH-treated HYPOX rats show more rapid spa-
tial memory acquisition in the MWM test. The dose of GH
sufficient for improving the performance in the MWM test
was suggested to be lower than that necessary for stimulating
somatic growth in HYPOX rats. We were unable to demon-
strate that rats who received 200 μ g/kg of GH twice daily per-
formed better in the MWM test than those who received 200
μ g/kg of GH once daily.
We also suggest that parameters such as body weight, the
width of the tibial epiphyseal plate, and spatial performance
in the MWM test may be appropriate to evaluate the effects
of GH administration by other routes, such as oral or intra-
tracheal. Further studies are needed to explain the basic mech-
anisms of the effects of GH on cognitive function. And, the
optimal doses of GH for improving cognitive function in
human must be decided.
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